CYDY is busy. They are rapidly gathering insight
Post# of 148126
(Total Views: 515)
Posted On: 09/03/2021 12:59:17 AM
CYDY is busy.
They are rapidly gathering insight on their drug leronlimab and how it can be applied to treat many diseases.
HIV combo therapy phase 3 USA completed,
met primary endpoint ,
The BLA is being filed in sections and filing completion is expected in October
HIV mono therapy phase 3 USA
HIV PrEP study coming
Covid19 mild & moderate cases 2 doses phase 2 USA completed,
met secondary endpoint
Covid19 severe & critical cases 2 doses phase 2b/3 USA completed,
strong results in subgroup
Covid19 severe cases 4 doses phase 3 (Brazil calls it moderate) APPROVED to start
Covid19 critical cases 4 doses administered by IV phase 3 (Brazil) APPROVED to start
Covid19 longhaulers phase 2 USA completed,
at least 8 p-values less than .05
Covid19 longhaulers phase 3 USA coming
Covid19 longhaulers phase 3 India possibly coming
mTriple Negative Breast Cancer phase 1b/2 USA
570 - 980% increase in 12 month survival
possibly will be presented in 2021
Cancer solid tumor basket trial phase 2 USA ongoing
NASH phase 2 USA at full 60 enrollment (700mg), ongoing
company wants 30 more at 350mg
"NASH takes a long time to enroll, and many trials can take years. We believe this is the fastest NASH trial ever"
Developing a central repository for all of our biomarkers
"of which we can then learn from one indication to the next"
Biomarker diagnostic test laboratory & biomarker diagnostic test in development.
"It will make it easier for practitioners"
Publishing papers on HIV, Covid19 (Mild, Moderate, Severe, Critical, LongHaulers) are being prioritized.
They have partners in Brazil, India, & Philippines
They have drug inventory & 2 manufacturing partners
https://s3.amazonaws.com/content.stockpr.com/...4/cyto.mp4
They are rapidly gathering insight on their drug leronlimab and how it can be applied to treat many diseases.
HIV combo therapy phase 3 USA completed,
met primary endpoint ,
The BLA is being filed in sections and filing completion is expected in October
HIV mono therapy phase 3 USA
HIV PrEP study coming
Covid19 mild & moderate cases 2 doses phase 2 USA completed,
met secondary endpoint
Covid19 severe & critical cases 2 doses phase 2b/3 USA completed,
strong results in subgroup
Covid19 severe cases 4 doses phase 3 (Brazil calls it moderate) APPROVED to start
Covid19 critical cases 4 doses administered by IV phase 3 (Brazil) APPROVED to start
Covid19 longhaulers phase 2 USA completed,
at least 8 p-values less than .05
Covid19 longhaulers phase 3 USA coming
Covid19 longhaulers phase 3 India possibly coming
mTriple Negative Breast Cancer phase 1b/2 USA
570 - 980% increase in 12 month survival
possibly will be presented in 2021
Cancer solid tumor basket trial phase 2 USA ongoing
NASH phase 2 USA at full 60 enrollment (700mg), ongoing
company wants 30 more at 350mg
"NASH takes a long time to enroll, and many trials can take years. We believe this is the fastest NASH trial ever"
Developing a central repository for all of our biomarkers
"of which we can then learn from one indication to the next"
Biomarker diagnostic test laboratory & biomarker diagnostic test in development.
"It will make it easier for practitioners"
Publishing papers on HIV, Covid19 (Mild, Moderate, Severe, Critical, LongHaulers) are being prioritized.
They have partners in Brazil, India, & Philippines
They have drug inventory & 2 manufacturing partners
https://s3.amazonaws.com/content.stockpr.com/...4/cyto.mp4
(12)
(0)CytoDyn Inc (CYDY) Stock Research Links
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.
Scroll down for more posts ▼